Navigation Links
NW BIO ANNOUNCES PRICING OF $17.5 MILLION OFFERING OF CONVERTIBLE NOTES
Date:8/14/2014

lawful.  Any offers of the securities will be made only by means of a private offering memorandum pursuant to Rule 144A under the Act. 

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all inoperable solid tumors cancers and has completed enrollment in the Phase I portion of the trial.  The Company previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer. The Company conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania.  In Germany, the Company recently received approval of a 5-year Hospital Exemption for treatment of glioma (brain cancer) patients outside the clinical trial.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vermillion Announces Additions to Commercial Management Team
2. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
3. Veracyte, Inc. Announces Second Quarter 2014 Financial Results
4. Hanger Announces Appointment of Asif Ahmad to Board of Directors
5. BiOptix Announces Additional $1.4M in Funding to Aid in Commercialization and Working Capital Needs
6. Perrigo Company plc Announces Quarterly Dividend
7. Kindred Biosciences Announces Second Quarter 2014 Financial Results
8. Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update
9. WuXi PharmaTech Announces Second-Quarter 2014 Results
10. Nutrastar International Inc. Announces Second Quarter 2014 Results
11. Novogen Announces Results of General Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... TWi Pharmaceuticals, Inc. ("TWi") today announced ... with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals ... Inc. (individually and collectively, "Takeda") to settle and ... generic dexlansoprazole delayed release capsules for oral administration ... Abbreviated New Drug Application for TWi,s generic product ...
(Date:4/25/2015)... -- Hospira, Inc. (NYSE: HSP ... sprach heute auf der jährlichen Konferenz der Europäischen ... London über die Bedeutung von ... für Patienten. Das Unternehmen kündigte auch ... Titel „Why extrapolation is paramount to achieving ...
(Date:4/24/2015)... 24, 2015 Today, humanity takes a massive step ... and fat-free cronuts: 1-800 CONTACTS announces their new Apple Watch ... two taps. Two taps. New contacts. From your ... The app also features LensGauge which helps keep track of ... need to reorder. "Since our inception, we,ve been ...
Breaking Medicine Technology:TWi Announces Settlement with Takeda on Dexilant(R) Litigation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 3Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 4Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 5Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 6Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 7Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 8Attention: We live in the future. Order contact lenses from your wrist with the 1-800 CONTACTS app for Apple Watch 2
(Date:4/27/2015)... Mirada, CA (PRWEB) April 27, 2015 ... minimally invasive treatments for nail fungi and infections. Onychomycosis, ... to affect up to 10% of adults in the ... fragility, and irregularity in thickness. , Healthpointe’s ... Institute , a branch dedicated to providing quality skincare ...
(Date:4/27/2015)... Miami, FL (PRWEB) April 27, 2015 ... policies from arresting nonviolent drug offenders to providing drug ... by Nepr on April 8th. Several states, ... cut state costs revolving incarceration. Texas has formed community ... populace. According to The Council of State Governments ...
(Date:4/27/2015)... April 27, 2015 Consumer Choice ... Service Providers in their respective sectors for Ottawa. We ... year’s winners; your dedication to superior service has resonated ... Canada, Consumer Choice Award gathers opinions, perceptions and expectations ... All winners have gone through a rigorous selection process ...
(Date:4/27/2015)... 2015 The Sanford J. Grossman Charitable ... Grossman, PhD, has committed $3 million to establish the ... Inflammatory Bowel Disease at the Icahn School of Medicine ... personalized medicine for treatment of Crohn’s disease, with the ... Crohn’s Disease, a chronic inflammatory disorder of the bowel ...
(Date:4/27/2015)... April 27, 2015 Final Cut Pro ... footage with ProTelestrator from Pixel Film Studios. A telestrator is ... sketch over a moving or still video image. Telestrators are ... analyze sports plays or incoming weather patterns. , After users ... then adjust the frame slider to control the speed of ...
Breaking Medicine News(10 mins):Health News:Southern California Healthpointe Clinics Now Treating Nail Fungus 2Health News:Texas Saves $443 Million Embracing Justice Reinvestment for Drug Charges 2Health News:Texas Saves $443 Million Embracing Justice Reinvestment for Drug Charges 3Health News:2015 Ottawa Consumer Choice Award-Winners 2Health News:2015 Ottawa Consumer Choice Award-Winners 3Health News:2015 Ottawa Consumer Choice Award-Winners 4Health News:2015 Ottawa Consumer Choice Award-Winners 5Health News:2015 Ottawa Consumer Choice Award-Winners 6Health News:2015 Ottawa Consumer Choice Award-Winners 7Health News:Sanford J. Grossman Charitable Trust Pledges $3 Million to Create Center at Mount Sinai 2Health News:Sanford J. Grossman Charitable Trust Pledges $3 Million to Create Center at Mount Sinai 3Health News:Pixel Film Studios releases ProTelestrator for Final Cut Pro X. 2
... has been discovered by researchers at Seoul National University. It ... highly expressed in lung cancer cells and also that patients ... study is published on March 31 in the open-access journal ... of the world,s most common cancers and a leading cause ...
... cancer organizations shows rates of death in the United States from ... and 2007. The findings come from the latest Annual Report to ... also finds that the overall rate of new cancer diagnoses for ... 1 percent per year for the same period. Edward J. ...
... from the University of Pittsburgh and Stanford University discovered ... role in the ability of one the world,s most ... possible role of similarly errant proteins in other diseases. ... the National Academy of Sciences ( PNAS ) ...
... the obesity epidemic, the National Institutes of Health is ... for NIH Obesity Research. More than one-third ... percent of the nation,s children are now obese, which ... including type 2 diabetes, heart disease, high blood pressure, ...
... a total of $383,000 for chronic obstructive pulmonary disease ... Institute (NHLBI), part of the National Institutes of Health, ... COPD Learn More Breathe Better campaign and will be ... The contract supports community-based public health efforts to ...
... continues to grow. Following the successful First International ... Second International Conference on Immune Tolerance will bring ... and insights into the mechanisms and treatment of ... inflammation and cancer. This Conference is supported by ...
Cached Medicine News:Health News:Pitt-Stanford research suggests aimless proteins crucial to disease 2Health News:New strategic plan for NIH obesity research seeks to curb epidemic 2Health News:NHLBI funds 9 organizations to improve awareness of COPD 2Health News:2nd International Conference on Immune Tolerance 2
Optoelectronic stimulator, "ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Pattern stimulations for ERG and VEP, multifocal stimulations for ERG and VEP, complies with international...
... The VISULAS 690s is ... As the instrument of choice ... Visudyne clinical trials, Carl Zeiss ... legacy in laser manufacturing to ...
The SL 115 Classic Slit Lamp offers you high optical performance and convenient operation. It is not only the ideal instrument for all routine examinations and contact lens fitting, but is also excel...
Lens Loading and Folding for Multipiece & Single-Piece ACRYSOF Lens with Standard Forceps...
Medicine Products: